|
Invited Speakers:
|
|
Adjuvants
R. Rao Koganty, Ph.D, Senior Director, Research and Development and Chemistry, Biomira Inc.
Nicholas Valiante, Research Director, Chiron CorpGrayson B. Lipford, Ph.D., Director, Basic Research, Coley Pharmaceutical Group, Inc.
Kristen M. Hege, M.D., Senior Director, Clinical Research, Cell Genesys, Inc.Immune Monitoring
Ena Wang, M.D., Staff Scientist, Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, NIH
Birgit Schultes, Ph.D., Sr. Director, Research, Unither Pharmaceuticals T-Cell Based Immunotherapy
Peter P. Lee, M.D., Assistant Professor of Medicine, Stanford University
Ron Berenson, M.D., President, CEO, Xcyte Therapies, Inc.
Laszlo Radvanyi, Ph.D., Senior Research Scientist, Immunology Platform, Aventis Pasteur
Israel Lowy, M.D., Ph.D., Director, Clinical Sciences and Infectious Diseases, Medarex, Inc. Antigen Presenting Cells
David Avigan, M.D., Director, Hematologic Malignancy/Bone Marrow Transplant Program, Beth Israel Deaconess Medical Center
Mary Lynne Hedley, Ph.D., Senior Vice President, R&D, ZYCOS, Inc.
Reiner Laus, M.D., Vice President of Research and Development, Dendreon Corporation
Anish S. Majumdar, Ph.D., Director of Immunology, Geron Corporation Novel Therapeutic Approaches
Dennis Van Epps, Ph.D., Vice President, Research, CancerVax Corp.
Dr. Manfred Schuster, Project Manager, Molecular Biology, igeneon AG
Dr. Gillian Payne, Head, New TAP Research, TAP Development, ImmunoGen
Susan F. Slovin, M.D., Ph.D., Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center
Tony Mills, Vice President, Business Development, BioVex Ltd.
George C. Prendergast, Ph.D., Senior Investigator, Lankenau Institute for Medical Research From Bench to Market
Michael Salgaller, Ph.D., Senior Associate, Toucan Capital Corp.
Antony Newton, Senior Director, Program Management, Genzyme Corporation
Neal F. Gordon, Ph.D., Senior Vice President, Manufacturing Operations, Antigenics, Inc.
|
|